MX2012003041A - Uso de n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-( 4-metil-2-tienil)-1-ftalazinamina en el tratamiento de cancer resistente al agente antimitotico. - Google Patents
Uso de n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-( 4-metil-2-tienil)-1-ftalazinamina en el tratamiento de cancer resistente al agente antimitotico.Info
- Publication number
- MX2012003041A MX2012003041A MX2012003041A MX2012003041A MX2012003041A MX 2012003041 A MX2012003041 A MX 2012003041A MX 2012003041 A MX2012003041 A MX 2012003041A MX 2012003041 A MX2012003041 A MX 2012003041A MX 2012003041 A MX2012003041 A MX 2012003041A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- amg
- tumor
- cells
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24152709P | 2009-09-11 | 2009-09-11 | |
| PCT/US2010/048247 WO2011031842A1 (en) | 2009-09-11 | 2010-09-09 | N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012003041A true MX2012003041A (es) | 2012-06-27 |
Family
ID=43216900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012003041A MX2012003041A (es) | 2009-09-11 | 2010-09-09 | Uso de n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-( 4-metil-2-tienil)-1-ftalazinamina en el tratamiento de cancer resistente al agente antimitotico. |
Country Status (34)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013181462A1 (en) * | 2012-05-31 | 2013-12-05 | Amgen Inc. | Use of amg 900 for the treatment of cancer |
| CN103664737A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| WO2015046783A1 (en) | 2013-09-30 | 2015-04-02 | Korea Institute Of Radiological & Medical Sciences | Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising hrp-3 inhibitor |
| DK3068393T5 (da) | 2013-11-11 | 2022-08-22 | Amgen Inc | Kombinationsterapi som inkluderer en mdm2-inhibitor og et eller flere yderligere farmaceutisk aktive midler til behandlingen af kræftformer |
| EP3077392B1 (en) | 2013-12-03 | 2020-01-15 | Amgen Inc. | Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl - 2-thienyl)-1-phthalazinamine pharmaceutically acceptable salts and uses thereof |
| CN114634483B (zh) * | 2014-02-21 | 2024-08-13 | 弗洛斯特生物科技有限公司 | 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 |
| WO2017181087A1 (en) * | 2016-04-15 | 2017-10-19 | Felicitex Therapeutics, Inc. | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| EP3679040B1 (en) | 2017-09-08 | 2022-08-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| EP3807276B1 (en) | 2018-06-12 | 2025-12-10 | Amgen Inc. | Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| PH12021552922A1 (en) | 2019-05-21 | 2022-04-04 | Amgen Inc | Solid state forms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003304266A1 (en) * | 2003-07-03 | 2005-01-21 | Cambridge University Technical Services Ltd | Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
| EA018128B1 (ru) | 2006-01-23 | 2013-05-30 | Амген Инк. | Модуляторы аурора киназы, способы их получения и их применение |
| UA93538C2 (en) * | 2006-01-23 | 2011-02-25 | Амген Инк. | Aurora kinase modulators and method of use |
| US7560551B2 (en) * | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
| GB0609619D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Combination |
| GB0609621D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
-
2010
- 2010-09-09 ES ES10755044.4T patent/ES2528485T3/es active Active
- 2010-09-09 UA UAA201204585A patent/UA107675C2/ru unknown
- 2010-09-09 MX MX2012003041A patent/MX2012003041A/es active IP Right Grant
- 2010-09-09 HU HUE10755044A patent/HUE024568T2/hu unknown
- 2010-09-09 PH PH1/2012/500504A patent/PH12012500504A1/en unknown
- 2010-09-09 KR KR1020127009226A patent/KR20120082896A/ko not_active Ceased
- 2010-09-09 PT PT107550444T patent/PT2475368E/pt unknown
- 2010-09-09 RS RS20150065A patent/RS53807B1/sr unknown
- 2010-09-09 EP EP10755044.4A patent/EP2475368B1/en active Active
- 2010-09-09 JP JP2012528891A patent/JP5851403B2/ja active Active
- 2010-09-09 PL PL10755044T patent/PL2475368T3/pl unknown
- 2010-09-09 CA CA2773838A patent/CA2773838C/en active Active
- 2010-09-09 PE PE2012000323A patent/PE20120895A1/es not_active Application Discontinuation
- 2010-09-09 ME MEP-2015-10A patent/ME02048B/me unknown
- 2010-09-09 CN CN2010800512813A patent/CN102869361A/zh active Pending
- 2010-09-09 BR BR112012008325A patent/BR112012008325A2/pt not_active IP Right Cessation
- 2010-09-09 NZ NZ598758A patent/NZ598758A/en not_active IP Right Cessation
- 2010-09-09 SI SI201030865T patent/SI2475368T1/sl unknown
- 2010-09-09 EP EP14186203.7A patent/EP2818170B1/en active Active
- 2010-09-09 US US12/878,539 patent/US20120028917A1/en not_active Abandoned
- 2010-09-09 SG SG2012017422A patent/SG179102A1/en unknown
- 2010-09-09 HR HRP20150104AT patent/HRP20150104T1/hr unknown
- 2010-09-09 WO PCT/US2010/048247 patent/WO2011031842A1/en not_active Ceased
- 2010-09-09 EA EA201270383A patent/EA020526B1/ru not_active IP Right Cessation
- 2010-09-09 AU AU2010292225A patent/AU2010292225C1/en active Active
- 2010-09-09 DK DK10755044T patent/DK2475368T3/en active
- 2010-09-10 TW TW099130742A patent/TW201121956A/zh unknown
-
2012
- 2012-03-11 IL IL218569A patent/IL218569A0/en unknown
- 2012-03-12 TN TNP2012000110A patent/TN2012000110A1/en unknown
- 2012-03-12 CL CL2012000640A patent/CL2012000640A1/es unknown
- 2012-04-04 MA MA34753A patent/MA33658B1/fr unknown
- 2012-04-04 ZA ZA2012/02472A patent/ZA201202472B/en unknown
- 2012-04-10 CR CR20120171A patent/CR20120171A/es unknown
-
2013
- 2013-01-16 HK HK15106028.6A patent/HK1205457A1/en unknown
-
2015
- 2015-02-09 SM SM201500028T patent/SMT201500028B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2773838C (en) | Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer | |
| JP5872160B2 (ja) | 癌治療のための新規の組成物および方法 | |
| TR201802093T4 (tr) | Terapötik terapilerde kullanım için akt inhibitör bileşiği ve abirateron kombinasyonu. | |
| JP2013533846A (ja) | 抗転移化合物 | |
| US20160213669A1 (en) | Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer | |
| EP2922544A1 (en) | Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives | |
| KR20250067120A (ko) | 의학적 치료를 위한 시클린-의존성 키나제 2 억제제 | |
| WO2013149026A2 (en) | Use of n-(4-((3-(2-amino-4-pyrimidinyl) -2-pyridinyl)oxy)phenyl)-4-(4-methyl -2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer | |
| US10512631B2 (en) | Chalcone compounds | |
| HK1173655B (en) | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer | |
| JP2023514426A (ja) | アルテミシニン化合物、５－アミノレブリン酸またはメチル－５－アミノレブリン酸、および化学療法剤の医薬配合物 | |
| WO2021046178A1 (en) | Compounds and methods for treating cancer | |
| TW201936182A (zh) | Ｅｚｈ２抑制劑組合治療 | |
| CN107849033A (zh) | 用于治疗Rac‑GTP酶介导的病症的化合物 | |
| WO2016135140A1 (en) | 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer | |
| HK40027729A (en) | Ezh2 inhibitor combination therapies | |
| HK1248684B (en) | Usp7 inhibitor compounds and methods of use | |
| HK1248684A1 (zh) | Usp7抑制剂化合物及使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |